✦ LIBER ✦

431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors

✍ Scribed by S. Blagden; D. Olmos; R. Sharma; J. Barriuso; H. Medani; M. Versola; S. Murray; D.A. Smith; M.M. Dar; J.S. de Bono

Book ID: 119599587
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 80 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)72365-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Study of GSK461364, a Specific a

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

✍ Olmos, D.; Barker, D.; Sharma, R.; Brunetto, A. T.; Yap, T. A.; Taegtmeyer, A. B 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 988 KB

Phase 1 study of MLN8054, a selective in

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

✍ E. Claire Dees; Jeffrey R. Infante; Roger B. Cohen; Bert H. O’Neil; Suzanne Jone 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 328 KB

A phase I, dose-escalation study of the

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

✍ Patrick Schöffski; Ahmad Awada; Herlinde Dumez; Thierry Gil; Sylvie Bartholomeus 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 245 KB

A phase I, first-in-human dose-escalatio

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

✍ Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 232 KB

Phase I study of barasertib (AZD1152), a

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

✍ Gary K. Schwartz,Richard D. Carvajal,Rachel Midgley… 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 389 KB

36 ORAL A Phase I single dose escalation

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

✍ P. Schöffski; A. Awada; H. Dumez; T. Gil; S. Bartholomeus; J. Selleslach; M. Tat 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB